Autologous Cell Therapy Market Size and Trends

The Global Autologous Cell Therapy Market is estimated to be valued at USD 5.51 Bn in 2025 and is expected to reach USD 22.30 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 22.1% from 2025 to 2032.

Key Takeaways of the Autologous Cell Therapy Market:

By product type, the cell-based therapies segment is expected to contribute the highest share of the market with 43.1% in 2025.
By application, the oncology segment is expected to account for the largest share of the autologous cell therapy market with a share of 35.5% in 2025.
Based on technology, the stem cell therapy segment is expected to account for 46.2% share in 2025.
North America is expected to top the global market with 37.3% share, followed by Asia Pacific with 27.7% share in 2025.

Market Overview:

Advancements in cell processing and engineering techniques are enabling the development of personalized cell therapies. Targeted therapies and fewer side effects of autologous cell therapies compared to traditional treatment options are generating high demand. The market is witnessing significant growth due to increasing prevalence of chronic and life-threatening diseases globally. Rising investments by market players for research and development activities to develop innovative autologous cell therapy products is also fueling market expansion. Furthermore, favorable regulatory environment and reimbursement policies in developed economies are creating lucrative opportunities for market participants.

Autologous Cell Therapy Market Concentration By Players

To learn more about this report, Request sample copy

Key Developments:

In October 2024, Aspen Neuroscience, a biotechnology company, announced its participation in the 2024 Cell & Gene Meeting on the Mesa in Arizona, U.S. The company’s Chief Scientific Officer, Xiaokui Zhang, Ph.D., and Chief Technology Officer, Kim Raineri, will present the latest therapeutic and corporate developments. Dr. Zhang will participate in a panel titled "Science Slam: Neurological Diseases," discussing biomarkers and endpoints development for neurodegenerative diseases in the context of cell and gene therapy.
In March 2024, Gamida Cell Ltd., a clinical-stage biopharmaceutical company, secured a Restructuring Support Agreement with its primary lender, Highbridge Capital Management, to ensure long-term financial stability and aid the commercialization of Omisirge, (omidubicel-onlv) a groundbreaking advanced cell therapy.
In November 2023, Selecta Biosciences and Cartesian Therapeutics, biotechnology companies, merged to form a new entity under the Cartesian Therapeutics brand, focused on developing RNA cell therapies for autoimmune diseases. Trading under the ticker "RNAC" on Nasdaq, the newly formed company aims to leverage a combined cash balance of over US$ 110 million.
In March 2023, Adaptimmune and TCR2 Therapeutics, biopharmaceutical companies, announced a strategic all-stock merger to create a leading cell therapy company targeting solid tumors. This merger is expected to enhance clinical development and extend the company’s cash runway until 2026.
In January 2022, ProKidney, a biotech company, merged with Chamath Palihapitiya’s SPAC, raising US$ 825 million to fund phase 3 trials for their kidney disease cell therapy, ReACT. If successful, ProKidney’s treatment could capture a significant portion of the market, potentially earning US$ 16 billion.

Top Strategies Followed by Global Autologous Cell Therapy Market Players

Established players: Leading companies in the autologous cell therapy market, such as Bristol Myers Squibb and Gilead Sciences, are heavily investing in research and development to innovate high-performance products.
- For instance, Bristol Myers Squibb's CAR T-cell therapy, Breyanzi, received the USFDA approval in March 2024, showcasing their commitment to advancing treatment options for patients with relapsed or refractory large B-cell lymphoma.
Mid-level players are focusing on delivering quality, budget-friendly products. For example, companies like Vericel Corporation are developing cost-effective autologous therapies that cater to price-sensitive consumers.
Smaller companies often target niche markets with unique or innovative products. For example, Hemera, an Italy-based startup, is advancing cell therapy by using specific types of autologous immune cells to treat autoimmune diseases, addressing specific patient needs. Embracing cutting-edge technologies is crucial for competitiveness. Startups are integrating advanced gene-editing tools and automation to enhance the precision and scalability of autologous cell therapies.

Emerging Startups - Autologous Cell Therapy Industry Ecosystem

Many startups are engaging in the development of innovative technologies critical to the future of the industry. Companies like Oxgene and Pluristem are working on perfusion bioreactors and smart biosensors to optimize cell-processing protocols. Startup, Kiadis, uses proprietary “off-the-shelf” NK-cell technologies as alternatives to patient-specific approaches. Such advanced solutions aim to lower therapy costs and expand availability worldwide over the next decade.
Sustainability is a key focus area for emerging players. Various startups are pursuing eco-friendly initiatives like developing xeno-free and serum-free culture media from plant sources instead of animal-derived components. Some work on novel techniques to regenerate cells from cellulose waste and implement closed-loop manufacturing systems with zero liquid discharge. This helps reduce industry's dependence on finite resources and lower environmental footprint.
Many startups have found niche in addressing specific medical conditions overlooked by others. For example, Tmunity Therapeutics focuses on T-cell therapies for solid cancers while Mustang Bio concentrates on gene and chimeric antigen receptor (CAR) T-cell therapies for blood cancers. Such specialized innovation could transform treatment outcomes for different patient segments.